Elbasvir/grazoprevir plus sofosbuvir in treatment-naive and treatment-experienced cirrhotic patients with hepatitis C virus genotype 3 infection treated for 8, 12, or 16 weeks: final results of the C-ISLE study

GR Foster, K Agarwal, ME Cramp, S Moreea, S Barclay, J Collier, AS Brown, SD Ryder, A Ustianowski, DM Forton, R Fox, F Gordon, WM Rosenberg, DJ Mutimer, J Du, CL Gilbert, M Robertson, E Barr, B Haber

Research output: Contribution to conferenceConference paper (not formally published)peer-review

Original languageEnglish
DOIs
Publication statusPublished - Apr 2017

Cite this